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Wilson disease (WD) is an inherited copper metabolism dysfunction disease 
characterized by cirrhosis and CNS findings. Wilson disease is important because 
it is fatal if not recognized and treated. Our Goal of study is to investigate the 
clinical signs and symptoms, lab results and other relevant matters in our patients 
in order to obtain a better understanding of this potentially lethal disease in our 
country. 
Materials & Methods
We have evaluated 21 cases of children with Wilson disease who were referred 
to Loghman and Imam Hussein Hospital between years 1998-2005. The mean 
age of our patients was 9 years. 
Results
The presenting symptom was ascites and extremity edema in 6(28.5%) patients, 
behavioral changes or neurological signs in 5 (24%) simultaneous Ascites and 
icter in 9(43%) patients and  in one patient the presenting manifestation was 
hemolytic anemia(4.8%). One of our patients died because of fulminant hepatitis 
in the course of admission(4.8%).
Conclusion
we showed in this study that Wilson disease can be presented by a manifold 
symptoms in children and adolescence .Having a good concept of these 
symptoms and high clinical suspicious are required to diagnose this potentially 
lethal disease at the proper time in order to decrease the potential adverse 
effects of the disease especially the neuropsychiatric damages significantly.
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Introduction
Wilson disease (WD) is an inherited copper metabolism dysfunction disease 
characterized by cirrhosis and Central Nervous System (CNS) findings. An American 
neurologist, Samuel Alexander Kinnier Wilson, first described Wilson disease in 
1912 (1). Wilson identified seven patients with a new familial disorder presenting 
with progressive degeneration of the lenticular nuclei and liver cirrhosis at autopsy. 
Although Wilson hypothesized the presence of a toxin affecting the liver and the 
brain, the role of copper in disease pathogenesis was not recognized for another 35 
years (2). 
The condition is characterized by excessive deposition of copper in the liver, brain, 
RESEARCH ARTICLE
36 Iran J Child Neurology  Jan  2009
and other tissues. The major physiologic aberration is 
excessive absorption of copper from the small intestine 
and decreased excretion of copper by the liver (3). The 
genetic defect, localized to chromosome arm 13q, has 
been shown to affect the copper-transporting adenosine 
triphosphatase (ATPase) gene (ATP7B) in the liver(4).
Patients with Wilson disease usually present with 
liver disease during the first decade of life or with 
neuropsychiatric illness during the third decade. The 
diagnosis is confirmed by measurement of serum 
ceruloplasmin, urinary copper excretion, and hepatic 
copper content, as well as the detection of Kayser-
Fleischer rings (5). Although it is extremely rare in 
clinical practice, Wilson disease is important because 
it is fatal if not recognized and treated. Some have 
speculated that Wilson disease goes undiagnosed in one 
half of patients with the disease. Often, the diagnosis is 
not made until adulthood despite manifestations of the 
disease in childhood. 
In this study we have evaluated 21 cases of children 7-12 
years old with Wilson disease who referred to Loghman 
and Imam Hussein Hospital between years 1998-2005. 
Our Goal of study is to investigate the clinical signs and 
symptoms, lab results and other relevant matters in our 
patients in order to obtain a better understanding of this 
potentially lethal disease in our country.
Patients and Methods
Our study consists of 21 patient who were diagnosed 
as Wilson in Loghman and Imam Hussein Hospital 
during an eight year period (1998-2005).Our inclusion 
criteria for diagnosis of Wilson disease were a 
combination of clinical manifestations consisting of 
liver involvement, neurological signs and symptoms 
especially extrapyramidal symptoms,behavioral changes 
and Kayser-Fleischer rings diagnosed by experienced 
corneal specialist and laboratory results consisting of 
Serum ceruloplasmin levels lower than 20 mg/dl, low 
total serum copper level and increased urinary copper 
excretion (>100 mcg/d).Liver biopsy was performed on 
19 patients to confirm the diagnosis and to assess the 
amount of hepatic damage. It is necessary to announce 
that patients with high probability of Wilson disease in 
whom initial Lab data refused to confirm the diagnosis 
and the measurement of hepatic copper was not available, 
were excluded from the study. All patients’ demographic, 
clinical, imaging and lab data were charted and analyzed 
using SPSS 14. It is necessary to announce that the 
patient’s confidentiality was completely respected in our 
study.
Results
Our study included 21 patients diagnosed by Wilson 
disease who came to us between years 1998-2005.The 
mean age of our patients was 9 years (figure-1).The sex 
distribution were 13 boys and 8 girls.
The presenting symptom in 6 patients was ascites and 
extremity edema. Behavioural changes and neurological 
signs, hemolytic anemis and simultaneous ascites and 
icter were other presenting symptoms in our patients 
(table-1).
On admission 12 cases had Kayser-Fleischer rings 
confirmed by corneal specialist. Hepatosplenmegaly and 
Fulminant hepatitis were other reported manifestations 
on admission (table-2). Liver Biopsy was performed on 
19 patients.All of them had histopathological changes 
compatible with liver cirrhosis mostly micronodular. 2 
patients refused to do liver biopsy.All but 3 patients didn’t 
report any adverse effect of penicillamine therapy during 
the course of admission. Malaise and worsening of the 
neurological symptoms were the adverse effects in these 
patients. 42.8% of our patients had neuropsychiatric 
symptoms. In 23.8% of cases it was the presenting 
manifestation of the disease (table -3).All of our cases 
with neuropsychiatric symptoms had Kayser-Fleischer 
rings. 
The laboratory evaluation of the patients included 
CBC, Billirubin, liver function tests, PT, PTT, Serum 
Ceruloplasmin and copper, Urinary copper, HbsAg and 
liver Biopsy (table-4). Among 18 patients with high 
serum billirubin, 8 had serum billirubin less than 4 mg/
dl. Of 4 patients with abnormal PT one died of fulminant 
hepatitis in the course of hospitalization. 
Serum ceruloplasmin level (normal, 20-60 mcg/dl), 
copper level (normal, 80-160 mcg/dl) and urinary 
excretion of copper (normal, 10-80 mcg/24 h) of our 
patients are reported in table-5. 62 % of 8 patients) 
with normal urinary excretion had high urinary copper 
(>100) on repeated collection after oral challenge with 
D-penicillamine 500 mg. High hepatic Copper content 
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(>250 µg/g dry weight) was the confirmatory test in 4 
patients for whom we had high clinical suspicion for 
Wilson disease but the other Lab tests refused to confirm 
the diagnosis of Wilson disease.
One patient was diagnosed with childhood rickets 1 
year before admission that could be due to the metabolic 
effect of the disease on skeletal system.
Discussion
Wilson disease (WD) is an inherited copper metabolism 
dysfunction disease characterized by cirrhosis and 
CNS findings. Although it is extremely rare in clinical 
practice, Wilson disease is important because it is fatal 
if not recognized and treated. Some have speculated that 
Wilson disease goes undiagnosed in one half of patients 
with the disease. Often, the diagnosis is not made until 
adulthood despite manifestations of the disease in 
childhood. It is very important for the pediatrician to 
be familiar with the presenting symptoms of Wilson 
disease in order to make an appropriate clinical decision 
at early stages of the disease.We tried to give a better 
understanding of this disease in our study in children.
This can be helpful for the patients in order to hinder the 
consequent damages of the disease especially to CNS by 
early treatment. 
The mean age of our patients were 9 years. Non of 
our patient was younger than six years old. Many 
studies have shown that children younger than 5 years 
rarely present with symptoms of Wilson disease(6). 
Our age group of patients is in accordance with the 
study conducted by Imanzadeh et al in our country that 
showed the most patients were in 8-9 and 10-11 years 
age group with 37% and 20%, respectively(7). In study 
by imanieh in shiraz,there were 4 years old children(8). 
The sex distribution were 61.9 % (13) boys and 32.1% (8 
cases) girls (p<0.005).This is in contrast to other studies 
results that show the equal prevalence of this disease 
between two sex groups.We could not find a reason for 
this discrepancy, and in the other study in IRAN boys 
were predominant(7,13). The fulminant presentation of 
Wilson disease is more common in females than in males 
(4:1).Our only patient with fulminate liver damage who 
died in hospital admission was female(9).
Hepatic dysfunction is the most common initial 
manifestation in childhood, with patients in this category 
presenting at an average age of 10-13 years, a decade 
or more sooner than those presenting with neurologic 
symptoms (10). The presenting symptom in 28.5 % of 
our patients was ascites and extremity edema. 43% of our 
patients had simultaneous Ascites and icter at the time 
of presentation. Almost all of our patients had a degree 
of hepatic involvement in History,physical examination 
or initial basic laboratory tests. It is confirmed by the 
fact that of 19 Liver biopsies that were performed all 
showed histopathological changes compatible with 
liver cirrhosis mostly micronodular. This is compatible 
with Davies et al study that showed Liver disease ranges 
from mild elevation of the serum transaminases in 
asymptomatic individuals to chronic active hepatitis and 
cirrhosis. In certain circumstances, the initial presentation 
may be that of acute liver failure accompanied by the 
sudden release of excess copper into the bloodstream 
with resultant hemolytic anemia (11). Davies et al 
showed that irrespective of the initial symptoms, almost 
all patients will have some evidence of cirrhosis on liver 
biopsy, reflecting the response to years of hepatic copper 
accumulation before clinical symptoms. Such biopsies 
may reveal micronodular cirrhosis with evidence of 
copper deposition in a variable distribution throughout 
the liver lobules. Eventually, this histology progresses to 
that of chronic hepatitis with nodular regeneration (12). 
In one of our patients the presenting manifestation was 
hemolytic anemia.It was reported in Schilsky et al study 
on liver transplantation in Wilson disease that in certain 
circumstances, the initial presentation may be that of 
acute liver failure accompanied by the sudden release 
of excess copper into the bloodstream with resultant 
hemolytic anemia. This process of rapid hepatic 
degeneration in a previously well-appearing individual 
suggests the presence of a viral illness or external factor 
that has triggered injury in a copper-loaded liver (13).
In our study which was performed on children age group 
only in 24 percent of the patients were the neuropsychiatric 
symptoms the obvious presenting manifestation of the 
disease.On detail physical and clinical examination 
42.8 % of patients had neuropsychiatric symptoms 
that is reported in detail in table-3. This is relatively 
in accordance with the study conducted by Oder W. 
They concluded that neurologic symptoms may occur 
at initial presentation in 60% of patients, usually in the 
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third or fourth decade of life, however in children the 
presentation of neurological symptoms are much less 
common and may be seen in 25-30% of the cases (14). 
However our results are lower than the results of the 
study of Imanzadeh et al that revealed neuropsychiatric 
abnormalities in 37% of patients (7). All of our cases 
with neuropsychiatric symptoms had Kayser-Fleischer 
rings,we had a group of best ophthalmogist with latest 
equipments..Because these symptoms arise from copper 
deposition in the central nervous system, awareness 
of Wilson’s disease as a possible cause can lead to 
early diagnosis and treatment with a rapid overall 
improvement. These underlying structural changes 
and the copper deposition can be detected by magnetic 
resonance imaging at an early stage in symptomatic 
patients and may be observed to decrease with chelation 
therapy (15). 42.8 % of our patients had psychiatric 
symptoms. These symtoms, defined in Dening et al 
study on psychiatric manifestations of Wilson disease, 
revealed that psychiatric illness may occur alone or in 
combination with other symptoms in the course of the 
disease and includes abnormal behavior, personality 
changes, depression, and cognitive impairment indicative 
of schizophrenia(16).
Laboratory evaluation to confirm the diagnosis of 
Wilson’s disease is warranted in anyone with isolated 
elevation of serum transaminases, chronic hepatitis 
of undetermined cause, Kayser-Fleischer rings, basal 
ganglia symptoms, or unexplained psychiatric illness, 
including sudden behavioral changes. In our study 
Low serum ceruloplasmin level of <20 mg/dl (normal, 
20-60 mcg/dl) was detected in all patients and 20 out 
of 21 patients had low copper level (normal, 80-160 
mcg/dl).This is in contrast to the study of Steindl et 
al who discussed Ceruloplasmin as an acute phase 
protein; thus this value will be in the normal range in 
5% of patients due to infection or inflammation (17,18). 
Another inexpensive screening test is measurement of 
urinary copper concentration. Martins da Costa C et 
al study concluded that in pediatric cases of WD—in 
particular those of the hepatic variety—a provocative 
test for urinary copper excretion using the chelating 
agent D-penicillamine has been undertaken, with high 
levels of sensitivity reported(19). This was confirmed by 
our study. While in 61.9 % of patients urinary excretion 
of copper was high >100 mcg/24 hours (normal, 10-80 
mcg/24 h) on the initial test, 62.5 % of 8 patients with 
normal urinary excretion had high urinary copper (>100 
) on repeated collection samples after oral challenge with 
D-penicillamine 500 mg.
One patient was diagnosed with childhood rickets 1 
year before admission that could be due to the metabolic 
effect of the disease on skeletal system.
Therapy with penicillamine is initiated as a test oral 
dose that if tolerated is then given four times daily. In 
our study 14.2 % of patients reported adverse effect of 
penicillamine therapy during the course of admission. 
Malaise and rash were the side effects in two patients. 
One patient experienced deterioration of neurological 
symptoms after treatment with D-penicillamine that 
made us stop the drug and change the therapy to 
zinc salt. This is lower than 20-30% exacerbation of 
neurological symptoms that was reported by Brewer 
et al in their study.Brewer et al study revealed that in 
20-30% of cases, an exacerbation of the neurological 
symptoms occurs over a period of 2 weeks to 12 months 
(commonly after 6 weeks). This occurrence is caused by 
the rapid mobilization of liver copper in the circulation, 
and can sometimes be permanent (20). The lower rate 
showed in our study can be due to a failure in precise 
follow-up or it can be caused by different age groups of 
the patients in two studies (children vs adults).
In our study low Hemoglubin was seen in 33.3 % (7)of 
patients. 4 patients had Iron deficiency anemia that 
was treated appropriately.Coombs-negative hemolytic 
anemia was the reason in 3.Our results are a confirmation 
to Schilsky et al study that proved acute release of copper 
into the circulation can damage red blood cells, thereby 
inducing hemolysis. They saw this phenomenon in 10-
15 % of patients with Wilson disease in the course of 
disease (21).
In conclusion, we showed in this study that Wilson 
disease can be presented by a manifold symptoms in 
children and adolescence.Having a good concept of 
these symptoms and high clinical suspicious are required 
to diagnose this potentially lethal disease at the proper 
time in order to decrease the potential adverse effects 
of the disease especially the neuropsychiatric damages 
significantly.
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Figure1: Age distribution of our patients
 Table1. Presenting symptoms of Wilson in our patients (n=21)
Presenting Symptom Number Percent
Ascites And Extremity Edema 6 28.5 %
Behavioral Changes Or Neurological Signs 5 24%
Hemolytic Anemia 1  4.8%
Simultaneous Ascites And Icter 9 43%
Total 21 100%
 Table 2. Physical Examination of patients on admission
Gastrointestinal Manifestaitons Number Percent 
Only Splenomegaly 1 5%
Only Hepatomegaly 2 9.5 %
Hepatosplenomegaly 18 85 %
Fulminant Hepatitis 1 4.8%
Total patients with abnormality 21 100%
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Table 3. Neuropsychiatric manifestations of Wilson disease on admission
Neuropsychiatric manifestations Number Percent 
As presenting symptom 5 24%
Behavioral Changes incuding irritability and poor concentration 6 28.5 %
Extrapyramidal signs including poor hand-writing 5 24%
Dysdiadochokinesia 3 14%
Total patients with neuropsychiatric manifestation 9 43%
 Table 4. Lab results in our patients, showing abnormal finding
Evaluation/Results Number Percent 
Low Hemoglubin due to Iron deficiency 4 19 %
Coombs-Negative hemolytic anemia 3 14 %
High serum billirubin 18 86 %
Elevated Aminotransferases 12 57 %
Abnormal PT 4 19 %
Table 5. Serum & Urinary copper profile of patients in our study
Parameter Number Percent
Low Serum Ceruloplasmin 15 71.5 %
Low Serum Copper 17 81 %
High urinary copper excretion 13 62 %
 
NEUROLOGICAL AND OTHER MANIFESTATIONS OF WILSON DISEASE; 1998-2005
41Iran J Child Neurology  Jan  2009
 References
1. Wilson SA. Progressive lenticular degeneration: a familial 
nervous disease associated with cirrhosis of the liver. 
Brain 1912; 34:295.
2. Cummings JN. The copper and iron content of the liver 
and brain in the normal and hepatolenticular degeneration. 
Brain 1948; 71:410-415.
3. Schilsky ML. Wilson disease: new insights into 
pathogenesis, diagnosis, and future therapy. Curr 
Gastroenterol Rep 2005 Feb; 7(1):26-31.
4. Schaefer M, Roelofsen H, Wolters H, Hofmann WJ, 
Mueller M, Kuipers F, et al. Localization of the Wilson’s 
disease protein in human liver. Gastroenterology 1999; 
117:1380-1385.
5. Brewer GJ. Recognition, diagnosis, and management of 
Wilson’s disease. Proc Soc Exp Biol Med   2000 Jan; 
223(1):39-46. 
6. McMillan JA, DeAngelis CD, Feigin RD, eds. Oski’s 
Pediatrics: Principles and Practice. Baltimore, Md. 
Lippincott ;Williams & Wilkins.1999.P.1721-2.
7. Imanzadeh FA, Sayyari A, Adib FB, Javaherizadeh HB, 
Fattah SB. Clinicopathologic findings in 35 children with 
Wilson disease. Jordan Medical Journal 2007; 41 (3):153-
156. 
8. Imanieh MH, Baragh Talab NH. survey of different kinds 
of clinical and laboratory findings on 46 wilson patients. 
Shahed Medical research Journal  1381;38 (9):7-14.
9. Brewer GJ. Recognition, diagnosis, and management of 
Wilson’s disease. Proc Soc Exp Biol Med   2000 Jan; 
223(1):39-46.
10. Walshe JM. Wilson’s disease presenting with features of 
hepatic dysfunction: A clinical analysis of eighty-seven 
patients. Q J Med 1989; 70:253-263.
11. Schilsky ML, Scheinberg IH, Sternlieb I. Liver 
transplantation for Wilson’s disease: Indications and 
outcome. Hepatology 1994; 19:583-587.
12. Davies SE, Williams R, Portmann B Hepatic morphology 
and histochemistry of Wilson’s disease presenting 
as fulminant hepatic failure: A study of 11 cases. 
Histopathology 1989;15:385-394.
13. Schilsky ML, Scheinberg IH, Sternlieb I. Liver 
transplantation for Wilson’s disease: Indications and 
outcome. Hepatology 1994; 19: 583.
14. Oder W, Grimm G, Kollegger H, Peter Ferenci P, 
Barbara Schneider B, Deecke L, et al. Neurologic 
and neuropsychiatric spectrum of Wilson’s disease: A 
prospective study of 45 cases. J Neurol 1991;238:281. 
15. Alanen A, Komu M, Penttinen M, Leino R. Magnetic 
resonance imaging and proton MR spectroscopy in 
Wilson’s disease. Br J Radiol. 1999;72:749-756.
16. Dening TR, Berrios GE. Wilson’s disease: Psychiatric 
symptoms in 195 cases. Arch Gen Psychiatry 
1989;46:1126-1134.
17. Steindl P, Ferenci P, Dienes HP, Grimm G, Pabinger I, 
Madl C.Wilson’s disease in patients presenting with 
liver disease: A diagnostic challenge. Gastroenterology 
1997;113:212-218.
18. Schilsky ML, Sternlieb I. Overcoming obstacles to the 
diagnosis of Wilson’s disease. Gastroenterology 1997; 
113:350-353.
19. Martins da Costa C, Baldwin D, Portmann B, Lolin Y, 
Mowat AP, Mieli-vergani G., et al. Value of urinary copper 
excretion after penicillamine challenge in the diagnosis of 
Wilson’s disease. Hepatology 1992;15: 609-615.
20. Brewer GJ. Penicillamine should not be used as initial 
therapy in Wilson’s disease. Mov Disord 1999; 14: 551-
554.
21. Schilsky M , Tavill AS. Wilson disease. In Disease of 
the Liver, (Eds Schiff ER et al.). ed,. 9 th, Philadelphia: 
Lippincott Williams & Wilkins;2003.P.1169-1186.
NEUROLOGICAL AND OTHER MANIFESTATIONS OF WILSON DISEASE; 1998-2005
